Rabkozol-L contains a combination of Rabeprazole Sodium 20 mg and Levosulpiride 75 mg, formulated for the management of acid-related and gastrointestinal motility disorders.
Rabeprazole is a proton pump inhibitor (PPI) that reduces gastric acid production, while Levosulpiride is a prokinetic agent that helps improve gastrointestinal motility. The combination may be prescribed for gastroesophageal reflux disease (GERD), acidity, heartburn, acid reflux, indigestion, bloating, and other gastrointestinal symptoms where impaired gastric motility may contribute to discomfort.
Each sustained-release capsule contains Rabeprazole Sodium 20 mg + Levosulpiride 75 mg and is manufactured under quality-controlled conditions under the KureKraft brand.